A 12-Week Open-Label Non-Interventional Evaluation of Atacand (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension.

Trial Profile

A 12-Week Open-Label Non-Interventional Evaluation of Atacand (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2009

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top